Ganciclovir - Have we established clinical value in the treatment of cytomegalovirus infections?

Academic Article


  • While treatment of herpes simplex and varicella-zoster virus infections, such as respiratory syncytial, influenza, and human immune deficiency viruses, has dominated clinical antiviral trials, recent reports of ganciclovir, also called 9-(1,3-dihydroxy-2-proxymethyl) guanine (DHPG), as a possible therapy for cytomegalovirus infection in high-risk, immunocompromised persons, have attracted increasing attention. A new drug application is currently under review by the Food and Drug Administration for ganciclovir therapy for cytomegalovirus chorioretinitis in immunocompromised patients (14-15). These new studies introduce two major considerations: host-virus interaction and the design of clinical trials to evaluate new therapies for high-risk patients.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Whitley RJ
  • Start Page

  • 452
  • End Page

  • 454
  • Volume

  • 108
  • Issue

  • 3